博瑞医药
(688166)
| 流通市值：224.07亿 | | | 总市值：224.07亿 |
| 流通股本：4.23亿 | | | 总股本：4.23亿 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 812,681,675.88 | 765,353,408.15 | 505,357,865.57 | 954,158,968.11 |
| 应收票据及应收账款 | 279,710,403.85 | 329,177,703.49 | 369,536,455.4 | 319,512,697.57 |
| 其中：应收票据 | 2,934,536.96 | 1,401,186.87 | 0 | 1,016,596.65 |
| 应收账款 | 276,775,866.89 | 327,776,516.62 | 369,536,455.4 | 318,496,100.92 |
| 应收款项融资 | 5,523,820.19 | 10,326,279.64 | 2,253,603.74 | 19,384,701.6 |
| 预付款项 | 49,610,071.01 | 104,833,585.27 | 107,954,668.17 | 46,917,582.05 |
| 其他应收款合计 | 2,025,851.04 | 6,662,961.27 | 3,032,209.5 | 2,890,743.76 |
| 其中:应收利息 | - | 0 | 0 | 0 |
| 应收股利 | - | 0 | 0 | 0 |
| 存货 | 365,680,037.04 | 364,614,796.55 | 339,742,470.71 | 330,269,983.6 |
| 其他流动资产 | 56,364,726.7 | 59,309,031.77 | 54,640,056.19 | 64,818,111.9 |
| 流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 流动资产合计 | 1,571,596,585.71 | 1,640,277,766.14 | 1,382,517,329.28 | 1,737,952,788.59 |
| 非流动资产: | | | | |
| 长期应收款 | 4,100,000 | 2,100,000 | - | - |
| 长期股权投资 | 37,969,215.94 | 39,043,408.27 | 39,325,778.89 | 41,588,602.44 |
| 其他权益工具投资 | 86,144,167.78 | 86,195,932.73 | 85,453,039.67 | 85,474,967.03 |
| 其他非流动金融资产 | 75,519,569.93 | 73,791,197.79 | 58,945,678.24 | 109,343,668.85 |
| 投资性房地产 | 58,845,712.57 | 59,566,335.25 | 60,286,957.93 | 61,007,580.61 |
| 固定资产 | 1,491,235,661.86 | 1,516,653,376.2 | 1,075,681,761.85 | 842,255,688.67 |
| 在建工程 | 1,201,042,721.66 | 1,167,043,420.42 | 1,621,450,042.69 | 1,779,599,927.9 |
| 使用权资产 | 20,859,929.19 | 21,548,596.91 | 23,513,017.43 | 26,993,922.36 |
| 无形资产 | 88,288,104.11 | 89,481,499.03 | 90,827,095.4 | 92,312,628.87 |
| 开发支出 | 183,674,072.4 | 14,337,087.12 | 9,258,962.26 | - |
| 商誉 | 3,120,100 | 3,120,100 | 7,500,000 | 7,500,000 |
| 长期待摊费用 | 42,545,333.66 | 43,149,414.93 | 28,604,665.65 | 38,326,305.07 |
| 递延所得税资产 | 82,358,685.61 | 73,547,013.46 | 56,071,439.09 | 55,492,646.2 |
| 其他非流动资产 | 337,973,436.39 | 334,491,009.23 | 339,097,043.42 | 352,819,435.25 |
| 非流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 非流动资产合计 | 3,713,676,711.1 | 3,524,068,391.34 | 3,496,015,482.52 | 3,492,715,373.25 |
| 资产平衡项目 | 0 | 0 | 0 | 0 |
| 资产总计 | 5,285,273,296.81 | 5,164,346,157.48 | 4,878,532,811.8 | 5,230,668,161.84 |
| 流动负债: | | | | |
| 短期借款 | 131,419,652.77 | 115,263,719.28 | 122,138,205.34 | 135,620,628.7 |
| 交易性金融负债 | 1,678,957.59 | 3,734,726.18 | 382,600 | 3,184,170.1 |
| 应付票据及应付账款 | 209,466,569.37 | 266,002,365.63 | 213,842,003.41 | 215,993,620.09 |
| 其中：应付票据 | 25,000,000 | 55,000,000 | 39,775,702.02 | 20,103,911 |
| 应付账款 | 184,466,569.37 | 211,002,365.63 | 174,066,301.39 | 195,889,709.09 |
| 合同负债 | 34,884,385.09 | 28,019,474.35 | 28,549,329.77 | 32,468,089.17 |
| 应付职工薪酬 | 43,140,065.45 | 51,809,244.02 | 14,637,196.78 | 14,402,534.99 |
| 应交税费 | 8,575,171.41 | 26,651,413.42 | 15,972,449.15 | 17,411,150.59 |
| 其他应付款合计 | 9,914,134.51 | 8,494,487.28 | 9,341,695.56 | 49,875,713.87 |
| 其中:应付利息 | - | 0 | 0 | 0 |
| 应付股利 | - | 0 | 0 | 40,521,898.78 |
| 一年内到期的非流动负债 | 480,935,520.71 | 537,366,789.87 | 463,613,234.3 | 527,574,129.86 |
| 其他流动负债 | 18,179,806.69 | 15,043,137.49 | 17,007,915.47 | 16,574,843.75 |
| 流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 流动负债合计 | 938,194,263.59 | 1,052,385,357.52 | 885,484,629.78 | 1,013,104,881.12 |
| 非流动负债: | | | | |
| 长期借款 | 1,155,361,436.71 | 1,109,933,478.66 | 1,104,249,061.43 | 1,268,314,033.31 |
| 应付债券 | 457,913,213.27 | 455,344,423.73 | 448,356,214.47 | 441,326,643.98 |
| 租赁负债 | 8,444,328.28 | 10,207,436.03 | 20,053,243.33 | 15,479,656.99 |
| 长期应付款 | 36,231,046 | 24,389,248.41 | 69,550,000 | 69,550,000 |
| 递延收益 | 73,112,154.99 | 74,710,350 | 8,500,000 | 8,750,000 |
| 非流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 非流动负债合计 | 1,731,062,179.25 | 1,674,584,936.83 | 1,650,708,519.23 | 1,803,420,334.28 |
| 负债平衡项目 | 0 | 0 | 0 | 0 |
| 负债合计 | 2,669,256,442.84 | 2,726,970,294.35 | 2,536,193,149.01 | 2,816,525,215.4 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 422,466,646 | 422,466,646 | 422,466,561 | 422,466,561 |
| 其他权益工具 | 75,639,147.66 | 75,639,147.66 | 75,639,635.72 | 75,639,635.72 |
| 永续债 | 75,639,147.66 | 75,639,147.66 | - | - |
| 资本公积 | 1,076,444,676.59 | 982,363,010.94 | 949,381,893.93 | 1,055,483,106.28 |
| 减:库存股 | 10,009,948.64 | 10,009,948.64 | 10,009,948.64 | 10,009,948.64 |
| 其他综合收益 | -122,185,574.81 | -122,115,353.67 | -119,642,893.27 | -119,418,660.46 |
| 盈余公积 | 85,464,856.69 | 85,464,856.69 | 67,219,535.13 | 67,219,535.13 |
| 未分配利润 | 973,798,977.73 | 960,839,201.64 | 967,326,338.8 | 896,282,320.1 |
| 归属于母公司股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 归属于母公司股东权益合计 | 2,501,618,781.22 | 2,394,647,560.62 | 2,352,381,122.67 | 2,387,662,549.13 |
| 少数股东权益 | 114,398,072.75 | 42,728,302.51 | -10,041,459.88 | 26,480,397.31 |
| 股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 股东权益合计 | 2,616,016,853.97 | 2,437,375,863.13 | 2,342,339,662.79 | 2,414,142,946.44 |
| 负债和股东权益合计 | 5,285,273,296.81 | 5,164,346,157.48 | 4,878,532,811.8 | 5,230,668,161.84 |
| 公告日期 | 2025-04-18 | 2025-04-03 | 2024-10-30 | 2024-08-24 |
| 审计意见(境内) | | 标准无保留意见 | | |